LRMR · CIK 1374690
What Larimar Therapeutics, Inc. told the SEC could break it.
Larimar Therapeutics is a clinical-stage biotech whose register reflects how much rides on one drug. It has never generated revenue, carries a $434.8 million accumulated deficit and expects continuing losses, so it depends on repeated equity raises to fund development of its lead candidate, nomlabofusp. That candidate's supply is fragile — its drug substance is made by a single third-party manufacturer — and even a successful eventual approval would meet U.S. drug-pricing pressure, including proposed CMS most-favored-nation models (GLOBE and GUARD) that would impose international-benchmark rebates on sole-source biologics.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- Pre-revenue clinical-stage company with large accumulated deficitmedium
Larimar has never generated revenue, has a $434.8M accumulated deficit, and expects continuing significant losses, leaving it dependent on repeated equity raises to fund development of its single lead candidate nomlabofusp.
“Since our inception, we have not generated any revenue from any sources, including from product sales, and have incurred significant operating losses and negative cash flows from our operations.”
SEC filing →As of 2026
Regulatory & policy
- Most-favored-nation drug-pricing models (GLOBE/GUARD) for sole-source biologicsmedium
Proposed CMS most-favored-nation models — GLOBE (Medicare Part B) and GUARD (Part D) — would require manufacturers of single-source drugs and sole-source biologics to pay incremental rebates tied to international reference prices, potentially compressing future pricing for nomlabofusp.
“the Global Benchmark for Efficient Drug Pricing Model (“GLOBE”) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS's spending and eligibility criteria.”
Supplier concentration
- Reliance on a small number of third-party manufacturers for drug substancemedium
Larimar relies on a small number of third-party manufacturers (the nomlabofusp drug substance is made by a single third party) for drug substance and formulated drugs, so a manufacturing disruption could halt its clinical and future commercial supply.
“The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch